We use cookies for a better user experience. Read our Privacy Policy

I Agree

Industry Verticals »

All Categories

Insights »

About TMR »

Dry Eye Disease Market

Schedule a Call

Dry Eye Disease Market

Dry Eye Disease Market (Product - Artificial Tears, Anti-inflammatory (Cyclosporine, Corticosteroid, and Lifitegrast), Punctal Plugs, and Secretagogue; Distribution Channel - Hospital Pharmacies, Independent Pharmacies & Drug Stores, and Online pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 - 2025

Global Dry Eye Disease Market: Snapshot

Dry eye disease is a common phenomenon which is likely to be experienced by an individual in his/her lifetime. Dry eye disease is a multifactorial disease which is characterized by insufficiency of tears in eye. Insufficient lubrication in eye lead to burning, sensing, redness and pain in eye. Dry eye disease is categorized into evaporative dry eye disease and aqueous deficiency dry eye diseases. Aqueous deficiency dry eye disease is mostly caused by Meibomian Gland Dysfunction (MGD), where in tear producing glands are insufficient to produce the tears. Dry eye disease is treated by various methods such as medications, medical device therapies and surgical interventions.

According to various studies conducted across the globe, the prevalence of dry eye disease is estimated to be in the range of 8% to 34%. There are various associated risk factors for dry eye disease such as ageing, diabetes, refractive surgeries such as LASIK, consumption of certain medications and environmental factors such as pollution. Rise in geriatric population across the globe is estimated to surge number of patients with dry eye disease. Key players are investing on development of new treatments for dry eye disease which is projected to drive expansion of the global market. However, many of the patients and physicians rely on over the counter available artificial tears for treatment of dry eye disease in initial stage. There are few prescription medications indicated for dry eye disease treatment which are comparatively expensive. Moreover these medications work on signs and symptoms of dry eye and doesn’t treat root cause of dry eye disease.    

Transparency Market Research estimates that the dry eye disease market will expand at a CAGR of 4.5% over the forecast period between 2017 and 2025. Escalating at this pace, the market, which had a valuation of US$ 5,045.2 Mn in 2016 in terms of revenue, is projected to rise to US$ 7,780.0 Mn by 2025.

gobal dry eye disease market

Demand for Anti-inflammatory Drugs to Remain High Through Forecast Period

The dry eye disease market has been segmented on the basis of product, distribution channel and geography. On the basis of product, anti-inflammatory drugs segment is projected to lead the market in terms of revenue and continues to dominate the market during the forecast period followed by artificial tears segment. Introduction of new anti-inflammatory drug such as Lifitegrast (Xiidra) and advancements in the existing cyclosporine eye drops is estimated to propel expansion of the segment. On the basis of distribution channel, the market is segmented into hospital pharmacies, independent pharmacies & drug stores and online pharmacies.

Rising Approval of Novel Drugs Pushes North America to Market’s fore

Geographically, dry eye disease market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominated the global dry eye disease market in terms of revenue in 2016 and is projected to retain its dominant position during the forecast period from 2017 to 2025. High adoption of prescription dry eye disease drugs in the U.S. and increasing number of approvals for new drugs and devices from the U.S. FDA are some of the major factors responsible for high share held by North America in 2016. Asia Pacific is anticipated to gain market share during the forecast period owing to large patient pool, increasing per capita health care expenditure and increasing investment of key players in this market.

Key companies profiled in the report include Santen Pharmaceutical Co., Ltd., Novartis AG, Valeant Pharmaceuticals International, Inc., Allergan plc, Shire plc, TRB Chemedica International SA, Sun Pharmaceutical Industries Ltd., Senju Pharmaceutical Co., Ltd., Sentiss Pharma Pvt. Ltd., Johnson & Johnson, Otsuka Pharmaceutical Co., Ltd., Mitotech S.A. and  FCI S.A.S.

Increasing Awareness and the Booming Geriatric Population to Accelerate the Growth of the Dry Eye Disease Market

With the rise in the geriatric population and the increasing number of eye-related disorders among them, the dry eye disease market is estimated to gain good growth prospects through the assessment period of 2017-2025. The growing prevalence of these diseases has urged many researchers and developers to discover good treatment options, which has eventually accelerated the growth prospects of the dry eye disease market.

  • Dry eye disease, also known as keratoconjunctivitis sicca (KCS) is a condition in which the tears present in an individual are not able to provide the right lubrication to the eyes. This tear instability can lead to inflammation and can also damage the eye surface. The growing emergence of novel treatments on the back of the intense research and development activities may bring tremendous growth opportunities for the dry eye disease market.
  • The increasing awareness about dry eye disease among a large number of individuals through various government and non-government initiatives will prove to be a prominent growth booster for the dry eye disease market. Furthermore, quick approvals for novel treatment measures from regulatory authorities will also bring good growth prospects for the dry eye disease market.
  • Strategic collaborations form an important part of the dry eye disease market. The players in the dry eye disease market are always involved in these activities for strengthening their hold. These activities eventually help in increasing the growth rate of the dry eye disease market.
  • The novel coronavirus pandemic has impacted the dry eye disease market to a considerable extent. The disruptions observed across the globe in terms of supply chain and logistics due to the lockdown restrictions have dented the growth prospects substantially. However, as the healthcare industry was exempted from the restrictions, the dry eye disease market was not affected much.

The global dry eye disease market has been segmented as follows:           

Product
  • Artificial Tears
  • Anti-inflammatory Drugs
  • Cyclosporine
  • Corticosteroids
  • Lifitegrast
  • Punctal Plugs
  • Secretagogue
  • Others

Distribution Channel
  • Hospital Pharmacies
  • Independent Pharmacies & Drug Stores
  • Online Pharmacies

Geography
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of MEA

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Dye Eye Disease Market

    4. Market Overview
         4.1. Introduction
                4.1.2. Industry Evolution / Developments
         4.2. Overview
         4.3. Market Dynamics
                4.3.1. Drivers
                         4.3.1.1. High prevalence and rise in incidence rates of dry eye disease and associated risk factors
                         4.3.1.2. Technical advancements and promising pipeline products
                         4.3.1.3. Novel dry eye diagnostic tools in offering
                         4.3.1.4. Growing number of eye care centers prompting surge in product utilization
                4.3.2. Restraints
                         4.3.2.1. High cost of specialty dry eye products with Unclear Reimbursement Scenario
                         4.3.2.2. Alternative therapies in offering
                4.3.3. Opportunities
                         4.3.3.1. Development of novel treatments
         4.4. Global Dye Eye Disease Market Analysis and Forecasts, 2015–2025
                4.4.1. Market Revenue Projections (US$ Mn)
         4.5. Porter’s Five Force Analysis
         4.6. Market Outlook
         4.7.Global Prevalence of Dry Eye Disease
         4.8.Pipeline Analysis : Dry Eye Disease Drugs
         4.9.Autologous Serum Tears – Overview
         4.10.Key Industry Trends

    5. Global Dye Eye Disease Market Analysis and Forecasts, By Product 
         5.1. Introduction & Definition
         5.2. Key Findings / Developments
         5.3. Key Trends
         5.4. Market value Forecast By Product, 2015–2025
                5.4.1. Artificial Tears
                5.4.2. Anti-inflammatory
                         5.4.2.1. Cyclosporine 
                         5.4.2.2. Corticosteroid
                         5.4.2.3. Lifitegrast
                5.4.3. Punctal Plugs
                5.4.4. Secretagogue
                5.4.5. Others
         5.5. Market Attractiveness By Product 

    6. Global Dye Eye Disease Market Analysis and Forecasts, By Distribution Channel 
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Key Trends
         6.4. Market value Forecast By Distribution Channel, 2015–2025
                6.4.1. Hospital Pharmacies
                6.4.2. Independent Pharmacies & Drug Stores
                6.4.3. Online Pharmacies
         6.5. Market Attractiveness By Distribution Channel 

    7. Global Dye Eye Disease Market Analysis and Forecasts, By Region
         7.1. Key Findings
         7.2. Market value Forecast By Region
                7.2.1. North America 
                7.2.2. Europe 
                7.2.3. Asia Pacific 
                7.2.4. Latin America 
                7.2.5. Middle East & Africa 
         7.3. Market Attractiveness By Region
         7.4. Key Trends, By Region

    8. North America Dye Eye Disease Market Analysis and Forecast
         8.1. Key Findings
         8.2. Market value Forecast By Product, 2015–2025
                8.2.1. Artificial Tears
                8.2.2. Anti-inflammatory
                         8.2.2.1. Cyclosporine 
                         8.2.2.2. Corticosteroid
                         8.2.2.3. Lifitegrast
                8.2.3. Punctal Plugs
                8.2.4. Secretagogue
                8.2.5. Others
         8.3. Market value Forecast By Distribution Channel, 2015–2025
                8.3.1. Hospital Pharmacies
                8.3.2. Independent Pharmacies & Drug Stores
                8.3.3. Online Pharmacies
         8.4. Market value Forecast By Country, 2015–2025
                8.4.1. US
                8.4.2. Canada
         8.5. Market Attractiveness Analysis 
                8.5.1. By Product 
                8.5.2. By Distribution Channel 
                8.5.3. By Country

    9. Europe Dye Eye Disease Market Analysis and Forecast
         9.1. Key Findings
         9.2. Market value Forecast By Product, 2015–2025
                9.2.1. Artificial Tears
                9.2.2. Anti-inflammatory
                         9.2.2.1. Cyclosporine 
                         9.2.2.2. Corticosteroid
                         9.2.2.3. Lifitegrast
                9.2.3. Punctal Plugs
                9.2.4. Secretagogue
                9.2.5. Others
         9.3. Market value Forecast By Distribution Channel, 2015–2025
                9.3.1. Hospital Pharmacies
                9.3.2. Independent Pharmacies & Drug Stores
                9.3.3. Online Pharmacies
         9.4. Market value Forecast By Country / Sub-region, 2015–2025
                9.4.1. Germany
                9.4.2. UK
                9.4.3. France
                9.4.4. Italy
                9.4.5. Spain
                9.4.6. Rest of Europe
         9.5. Market Attractiveness Analysis 
                9.5.1. By Product 
                9.5.2. By Distribution Channel 
                9.5.3. By Country / Sub-region

    10. Asia Pacific Dye Eye Disease Market Analysis and Forecast
         10.1.Key Findings
         10.2.Market value Forecast By Product, 2015–2025
                10.2.1. Artificial Tears
                10.2.2. Anti-inflammatory
                         10.2.2.1. Cyclosporine 
                         10.2.2.2. Corticosteroid
                         10.2.2.3. Lifitegrast
                10.2.3. Punctal Plugs
                10.2.4. Secretagogue
                10.2.5. Others
         10.3.Market value Forecast By Distribution Channel, 2015–2025
                10.3.1. Hospital Pharmacies
                10.3.2. Independent Pharmacies & Drug Stores
                10.3.3. Online Pharmacies
         10.4.Market value Forecast By Country / Sub-region, 2015–2025
                10.4.1. China
                10.4.2. Japan
                10.4.3. India
                10.4.4. Australia and New Zealand
                10.4.5. Rest of APAC
         10.5.Market Attractiveness Analysis 
                10.5.1. By Product 
                10.5.2. By Distribution Channel 
                10.5.3. By Country / Sub-region

    11. Latin America Dye Eye Disease Market Analysis and Forecast
         11.1.Key Findings
         11.2.Market value Forecast By Product, 2015–2025
                11.2.1. Artificial Tears
                11.2.2. Anti-inflammatory
                         11.2.2.1. Cyclosporine 
                         11.2.2.2. Corticosteroid
                         11.2.2.3. Lifitegrast
                11.2.3.Punctal Plugs
                11.2.4. Secretagogue
                11.2.5. Others
         11.3.Market value Forecast By Distribution Channel, 2015–2025
                11.3.1. Hospital Pharmacies
                11.3.2. Independent Pharmacies & Drug Stores
                11.3.3. Online Pharmacies
         11.4.Market value Forecast By Country / Sub-region, 2015–2025
                11.4.1. Brazil
                11.4.2. Mexico
                11.4.3. Rest of LATAM
         11.5.Market Attractiveness Analysis 
                11.5.1. By Product 
                11.5.2. By Distribution Channel 
                11.5.3. By Country / Sub-region

    12. Middle East & Africa Dye Eye Disease Market Analysis and Forecast
         12.1.Key Findings
         12.2.Market value Forecast By Product, 2015–2025
                12.2.1. Artificial Tears
                12.2.2. Anti-inflammatory
                         12.2.2.1. Cyclosporine 
                         12.2.2.2. Corticosteroid
                         12.2.2.3. Lifitegrast
                12.2.3. Punctal Plugs
                12.2.4. Secretagogue
                12.2.5. Others
         12.3.Market value Forecast By Distribution Channel, 2015–2025
                12.3.1. Hospital Pharmacies
                12.3.2. Independent Pharmacies & Drug Stores
                12.3.3. Online Pharmacies
         12.4.Market value Forecast By Country / Sub-region, 2015–2025
                12.4.1. GCC Countries
                12.4.2. South Africa
                12.4.3. Israel
                12.4.4. Rest of MEA
         12.5.Market Attractiveness Analysis 
                12.5.1. By Product 
                12.5.2. By Distribution Channel 
                12.5.3. By Country / Sub-region

    13. Competition Landscape
         13.1.Market Player – Competition Matrix (By Tier and Size of companies)
         13.2.Market Share Analysis By Company (2016)
         13.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
                13.3.1. Santen Pharmaceutical Co., Ltd.
                         13.3.1.1. Company Overview
                         13.3.1.2. Business Overview
                         13.3.1.3. Product Overview
                         13.3.1.4. Financial Overview
                         13.3.1.5. Strategic Overview
                         13.3.1.6. SWOT Analysis
                13.3.2. Novartis AG
                         13.3.2.1. Company Overview
                         13.3.2.2. Business Overview
                         13.3.2.3. Product Overview
                         13.3.2.4. Financial Overview
                         13.3.2.5. Strategic Overview
                         13.3.2.6. SWOT Analysis 
                13.3.3. Valeant Pharmaceuticals International, Inc. 
                         13.3.3.1. Company Overview
                         13.3.3.2. Business Overview
                         13.3.3.3. Product Overview
                         13.3.3.4. Financial Overview
                         13.3.3.5. Strategic Overview
                         13.3.3.6. SWOT Analysis
                13.3.4. Allergan plc 
                         13.3.4.1. Company Overview
                         13.3.4.2. Business Overview
                         13.3.4.3. Product Overview
                         13.3.4.4. Financial Overview
                         13.3.4.5. Strategic Overview
                         13.3.4.6. SWOT Analysis
                13.3.5. Shire plc 
                         13.3.5.1. Company Overview
                         13.3.5.2. Business Overview
                         13.3.5.3. Product Overview
                         13.3.5.4. Financial Overview
                         13.3.5.5. Strategic Overview
                         13.3.5.6. SWOT Analysis
                13.3.6. TRB Chemedica International SA 
                         13.3.6.1. Company Overview
                         13.3.6.2. Business Overview
                         13.3.6.3. Product Overview
                         13.3.6.4. Strategic Overview
                         13.3.6.5. SWOT Analysis
                13.3.7. Sun Pharmaceutical Industries Ltd. 
                         13.3.7.1. Company Overview
                         13.3.7.2. Business Overview
                         13.3.7.3. Product Overview
                         13.3.7.4. Financial Overview
                         13.3.7.5. Strategic Overview
                         13.3.7.6. SWOT Analysis
                13.3.8. Senju Pharmaceutical Co., Ltd. 
                         13.3.8.1. Company Overview
                         13.3.8.2. Business Overview
                         13.3.8.3. Product Overview
                         13.3.8.4. Financial Overview
                         13.3.8.5. Strategic Overview
                         13.3.8.6. SWOT Analysis
                13.3.9. Sentiss Pharma Pvt. Ltd. 
                         13.3.9.1. Company Overview
                         13.3.9.2. Business Overview
                         13.3.9.3. Product Overview
                         13.3.9.4. Strategic Overview
    \                     13.3.9.5. SWOT Analysis
                13.3.10. Johnson & Johnson 
                         13.3.10.1. Company Overview
                         13.3.10.2. Business Overview
                         13.3.10.3. Product Overview
                         13.3.10.4. Financial Overview
                         13.3.10.5. Strategic Overview
                         13.3.10.6. SWOT Analysis
                13.3.11. Otsuka Pharmaceutical Co., Ltd. 
                         13.3.11.1. Company Overview
                         13.3.11.2. Business Overview
                         13.3.11.3. Product Overview
                         13.3.11.4. Financial Overview
                         13.3.11.5. Strategic Overview
                         13.3.11.6. SWOT Analysis
                13.3.12. Mitotech S.A. 
                         13.3.12.1. Company Overview
                         13.3.12.2. Business Overview
                         13.3.12.3. Product Overview
                         13.3.12.4. Strategic Overview
                         13.3.12.5. SWOT Analysis
                13.3.13. FCI S.A.S. 
                         13.3.13.1. Company Overview
                         13.3.13.2. Business Overview
                         13.3.13.3. Product Overview
                         13.3.13.4. Strategic Overview
                         13.3.13.5. SWOT Analysis

    List of Tables 

    Table 01: Pipeline Analysis (1/5)
    Table 02: Pipeline Analysis (2/5)
    Table 03: Pipeline Analysis (3/5)
    Table 04: Pipeline Analysis (4/5)
    Table 05: Pipeline Analysis (5/5)
    Table 06: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
    Table 07: Global Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
    Table 08: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Distribution channel, 2015–2025
    Table 09: Global Dry Eye Disease Market Size (US$ Mn) Forecast, by Region, 2015–2025
    Table 10: North America Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
    Table 11: North America Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
    Table 12: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
    Table 13: North America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country, 2015–2025
    Table 14: Europe Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
    Table 15: Europe Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
    Table 16: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
    Table 17: Europe Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
    Table 18: Asia Pacific Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
    Table 19: Asia Pacific Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
    Table 20: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
    Table 21: Asia Pacific Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
    Table 22: Latin America Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
    Table 23: Latin America Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
    Table 24: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
    Table 25: Latin America Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025
    Table 26: Middle East & Africa Dry Eye Disease Market Size (US$ Mn) Forecast, by Product Type, 2015–2025
    Table 27: Middle East & Africa Dry Eye Disease Market Volume (Number of Units) Forecast, by Anti-inflammatory Drugs, 2015–2025
    Table 28: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Distribution channel, 2015–2025
    Table 29: Middle East & Africa Dry Eye Disease Market Value (US$ Mn) Forecast, by Country / Sub-region, 2015–2025

    List of Figures

    Figure 01: Dry Eye Disease Market Size (US$ Mn), by Product Type, 2016 (A)
    Figure 02: Dry Eye Disease Market Revenue (%), by Distribution channel, 2016 (A)
    Figure 03: Global Dry Eye Disease Market Revenue (%), by Region, 2016 (A)
    Figure 04: Product Type Revenue (%), 2016
    Figure 05: Distribution Channel Revenue  (%), 2016
    Figure 06: Global Dry Eye Disease Market Size (US$ Mn) Forecast, 2015–2025
    Figure 07: Market Value Share, by Product Type (2016)
    Figure 08: Market Value Share, by Distribution Channel (2016)
    Figure 09: Market Value Share, by Region (2016)
    Figure 10: Global Prevalence Dry eye Disease
    Figure 11: Global Dry Eye Disease Market Value Share, by Product Type, 2016 and 2025
    Figure 12: Global Dry Eye Disease Market Attractiveness, by Product Type, 2017–2025
    Figure 13: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Artificial Tears, 2015–2025
    Figure 14: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-inflammatory Drugs, 2015–2025
    Figure 15: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Punctal Plugs, 2015–2025
    Figure 16: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Secretagogue, 2015–2025
    Figure 17: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
    Figure 18: Global Dry Eye Disease Market Value Share, by Distribution channel, 2016 and 2025
    Figure 19: Global Dry Eye Disease Market Attractiveness, by Distribution channel, 2017–2025
    Figure 20: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2015–2025
    Figure 21: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Independent Pharmacies & Drug Stores, 2015–2025
    Figure 22: Global Dry Eye Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2015–2025
    Figure 23: Global Market Scenario
    Figure 24: Global Dry Eye Disease Market Value Share, by Region, 2016 and 2025 
    Figure 25: Global Dry Eye Disease Market Attractiveness, by Region, 2017–2025
    Figure 26: North America Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 27: North America Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 28: North America Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
    Figure 29: North America Dry Eye Disease Market Value Share Analysis, by Country, 2016 and 2025
    Figure 30: North America Dry Eye Disease Market Attractiveness Analysis, by Country
    Figure 31: North America Dry Eye Disease Market Attractiveness Analysis, by Product Type
    Figure 32: North America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
    Figure 33: Europe Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 34: Europe Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 35: Europe Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
    Figure 36: Europe Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
    Figure 37: Europe Dry Eye Disease Market Attractiveness Analysis, by Country  / Sub-region
    Figure 38: Europe Dry Eye Disease Market Attractiveness Analysis, by Product Type
    Figure 39: Europe Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
    Figure 40: Asia Pacific Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 41: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 42: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
    Figure 43: Asia Pacific Dry Eye Disease Market Value Share Analysis, by Country  / Sub-region, 2016 and 2025
    Figure 44: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Country  / Sub-region
    Figure 45: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Product Type
    Figure 46: Asia Pacific Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
    Figure 47: Latin America Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 48: Latin America Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 49: Latin America Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
    Figure 50: Latin America Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
    Figure 51: Latin America Dry Eye Disease Market Attractiveness Analysis, by Country / Sub-region
    Figure 52: Latin America Dry Eye Disease Market Attractiveness Analysis, by Product Type
    Figure 53: Latin America Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
    Figure 54: Middle East & Africa Dry Eye Disease Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
    Figure 55: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Product Type, 2016 and 2025
    Figure 56: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Distribution channel, 2016 and 2025
    Figure 57: Middle East & Africa Dry Eye Disease Market Value Share Analysis, by Country / Sub-region, 2016 and 2025
    Figure 58: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Country  / Sub-region
    Figure 59: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Product Type
    Figure 60: Middle East & Africa Dry Eye Disease Market Attractiveness Analysis, by Distribution Channel
    Figure 61: Global Dry Eye Disease Market Share Analysis, by Company (2016)
    Figure 62: Santen Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 63: Santen Pharmaceutical Co., Ltd. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 64: Santen Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016
    Figure 65: Novartis AG.  Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 66: Novartis AG. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 67: Novartis AG. Breakdown of Net Sales, By Region, 2016
    Figure 68: Valeant Pharmaceuticals International, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 69: Valeant Pharmaceuticals International, Inc. R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2014–2016
    Figure 70: Valeant Pharmaceuticals International, Inc. Breakdown of Net Sales, By Business Segment, 2016
    Figure 71: Allergan plc  Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 72: Allergan plc R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 73: Allergan plc Breakdown of Net Sales, By Business Segment, 2016
    Figure 74: Shire plc Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 75: Shire plc R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 76: Shire plc Breakdown of Net Sales, By Business Segment, 2016
    Figure 77: Sun Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 78: Sun Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 79: Sun Pharmaceutical Industries Ltd. Breakdown of Net Sales, By  Region, 2016
    Figure 80: Senju Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 81: Senju Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016
    Figure 82: Johnson & Johnson  Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 83: Johnson & Johnson R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 84: Johnson & Johnson Breakdown of Net Sales, By Business Segment, 2016
    Figure 85: Otsuka Pharmaceutical Co., Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 86: Otsuka Pharmaceutical Co., Ltd.  R&D Expenditure (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 87: Otsuka Pharmaceutical Co., Ltd. Breakdown of Net Sales, By Business Segment, 2016

Google translate

Copyright © Transparency Market Research, Inc. All Rights reserved